Home Companies Catalysts Deep Dives
Nplate romiplostim APPROVED
Drug Profile
ModalityFusion protein
RouteSC
Therapy AreaHematology
Launch2008-08-22
Peak Sales Est$1600M
Formulations[{"id":"nplate-sc","doses":"Weight-based, SC injection","route":"SC","setting":"HCP_ADMINISTERED","f
Companies
AMGN (ORIGINATOR)100%
Mechanism: Thrombopoietin receptor agonist
Expert: Small molecule agonist of the thrombopoietin receptor, stimulating megakaryopoiesis
Everyday: Stimulates production of platelets
Targets: ["TPOR"]
Revenue History
PeriodRevenue ($M)
2024$1,456M
2025$1,524M
Programs (1)
IndicationStageKey StudyRegional Status
ITPAPPROVEDPivotal ITP trials[{"stage":"APPROVED","region":"US","approval_date":"2008-08-22"},{"stage":"APPRO
Data from Supabase · Updated 2026-03-24